SG11201407226WA - Improved methods of cell culture for adoptive cell therapy - Google Patents

Improved methods of cell culture for adoptive cell therapy

Info

Publication number
SG11201407226WA
SG11201407226WA SG11201407226WA SG11201407226WA SG11201407226WA SG 11201407226W A SG11201407226W A SG 11201407226WA SG 11201407226W A SG11201407226W A SG 11201407226WA SG 11201407226W A SG11201407226W A SG 11201407226WA SG 11201407226W A SG11201407226W A SG 11201407226WA
Authority
SG
Singapore
Prior art keywords
cells
international
day
street
bellaire
Prior art date
Application number
SG11201407226WA
Inventor
Juan F Vera
Cliona M Rooney
Ann M Leen
John R Wilson
Original Assignee
Wolf Wilson Mfg Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49584374&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201407226W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/475,700 external-priority patent/US8956860B2/en
Application filed by Wolf Wilson Mfg Corp filed Critical Wolf Wilson Mfg Corp
Publication of SG11201407226WA publication Critical patent/SG11201407226WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/02—Form or structure of the vessel
    • C12M23/08—Flask, bottle or test tube
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
    • C12M25/02—Membranes; Filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/46447—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Sustainable Development (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Clinical Laboratory Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Absorbent Articles And Supports Therefor (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 November 2013 (21.11.2013) WIPOIPCT (10) International Publication Number WO 2013/173835 A1 (51) International Patent Classification: C12M 3/02 (2006.01) C12M 3/06 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/041861 20 May 2013 (20.05.2013) English English (30) Priority Data: 13/475,700 18 May 2012 (18.05.2012) US (71) Applicant: WILSON WOLF MANUFACTURING CORPORATION [US/US]; 33 5th Avenue NW, Suite 700, New Brighton, MN 55112 (US). (72) Inventors: VERA, Juan F.; 5227 Maple Street, Bellaire, TX 77401 (US). ROONEY, Cliona M.; 4802 Willow Street, Bellaire, TX 77401 (US). LEEN, Ann M.; 5227 Maple Street, Bellaire, TX 77401 (US). WILSON, John R.; 173 Windsor Lane, New Brighton, MN 55112 (US). (74) Agents: DICKSON, Thomas G. et al.; Patterson Thuente Pedersen, P.A., 4800 IDS Center, 80 South Eighth Street, Minneapolis, MN 55402-2100 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: IMPROVED METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY m oo m i> Su < o a. w JH INCREASE T ETRAM£R DAY 16 DAY 23 INCREASETETRAMER DAVO DAY 9 DAY 16 DAY 23 TIME IN CULTURE o CJ (57) Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the pres - ence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm 2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm 2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5x10 6 cells/cm 2 at the onset of production cycle, and a the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25 xlO 5 cells/cm . 2
SG11201407226WA 2012-05-18 2013-05-20 Improved methods of cell culture for adoptive cell therapy SG11201407226WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/475,700 US8956860B2 (en) 2009-12-08 2012-05-18 Methods of cell culture for adoptive cell therapy
PCT/US2013/041861 WO2013173835A1 (en) 2012-05-18 2013-05-20 Improved methods of cell culture for adoptive cell therapy

Publications (1)

Publication Number Publication Date
SG11201407226WA true SG11201407226WA (en) 2014-12-30

Family

ID=49584374

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201509930RA SG10201509930RA (en) 2012-05-18 2013-05-20 Improved methods of cell culture for adoptive cell therapy
SG11201407226WA SG11201407226WA (en) 2012-05-18 2013-05-20 Improved methods of cell culture for adoptive cell therapy
SG10202111564SA SG10202111564SA (en) 2012-05-18 2013-05-20 Improved methods of cell culture for adoptive cell therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201509930RA SG10201509930RA (en) 2012-05-18 2013-05-20 Improved methods of cell culture for adoptive cell therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202111564SA SG10202111564SA (en) 2012-05-18 2013-05-20 Improved methods of cell culture for adoptive cell therapy

Country Status (8)

Country Link
EP (2) EP2850175B1 (en)
JP (5) JP6386447B2 (en)
CN (2) CN104379727A (en)
AU (4) AU2013262485B2 (en)
CA (1) CA2872504A1 (en)
IL (3) IL307674A (en)
SG (3) SG10201509930RA (en)
WO (1) WO2013173835A1 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
IL302514A (en) * 2012-06-11 2023-07-01 Wilson Wolf Mfg Corporation Improved methods of cell culture for adoptive cell therapy
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
CN105296341A (en) * 2015-11-30 2016-02-03 苏州钧隆塑胶有限公司 Efficient guide tube bacterium culturing bottle
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
BR112019000185A2 (en) 2016-07-07 2019-04-16 Iovance Biotherapeutics, Inc. protein, nucleic acid, cell, and methods for producing a genetically modified cytotoxic lymphocyte, for treating an individual who has or is suspected of having cancer and for reducing the interaction between pd-1 in a first cell and pd-1 in a second cell.
HRP20240436T1 (en) 2016-10-26 2024-06-21 Iovance Biotherapeutics, Inc. Restimulation of cryopreserved tumor infiltrating lymphocytes
TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
KR102618948B1 (en) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. Residual tumor infiltrating lymphocytes and methods of making and using the same
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
TW201837168A (en) 2017-01-06 2018-10-16 美商艾歐凡斯生物治療公司 Expansion of tumor infiltrating lymphocytes (TILS) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILS and TNFRSF agonists
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (en) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20200224161A1 (en) 2017-05-10 2020-07-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
PE20200303A1 (en) 2017-05-24 2020-02-06 Novartis Ag ANTIBODY PROTEINS GRAFTED WITH CYTOKINE AND METHODS OF USE IN THE TREATMENT OF CANCER
TW201919662A (en) 2017-06-05 2019-06-01 美商艾歐凡斯生物治療公司 Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
AU2018368786A1 (en) 2017-11-17 2020-06-18 Iovance Biotherapeutics, Inc. TIL expansion from fine needle aspirates and small biopsies
JP2021503885A (en) 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood
US20210369775A1 (en) 2017-12-15 2021-12-02 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
TW201938177A (en) 2018-01-08 2019-10-01 美商艾歐凡斯生物治療公司 Processes for generating TIL products enriched for tumor antigen-specific T-cells
SG11202009170UA (en) 2018-03-29 2020-10-29 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
EP3784254A1 (en) 2018-04-27 2021-03-03 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
TW202031273A (en) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 Treatment of nsclc patients refractory for anti-pd-1 antibody
IL281423B1 (en) 2018-09-20 2024-04-01 Iovance Biotherapeutics Inc Expansion of tils from cryopreserved tumor samples
SG11202104663PA (en) 2018-11-05 2021-06-29 Iovance Biotherapeutics Inc Treatment of nsclc patients refractory for anti-pd-1 antibody
BR112021008573A2 (en) 2018-11-05 2021-10-26 Iovance Biotherapeutics, Inc. METHODS TO EXPAND TUMOR-INFILTRATING LYMPHOCYTES IN A TUMOR-INFILTRATING LYMPHOCYTE THERAPY POPULATION, TO TREAT A SUBJECT WITH CANCER AND T-CELL EXPANSION, TUMOR-INFILTRATING LYMPHOCYTE THERAPEUTIC POPULATION, TUMOR-INFILTRATING LYMPHOCYTE COMPOSITION, INFANT BAG, CRYOPRESERVED PREPARATION, AND, USE OF TUMOR-INFILTRATING LYMPHOCYTE COMPOSITION.
MX2021004775A (en) 2018-11-05 2021-06-08 Iovance Biotherapeutics Inc Expansion of tils utilizing akt pathway inhibitors.
SG11202104630PA (en) 2018-11-05 2021-06-29 Iovance Biotherapeutics Inc Selection of improved tumor reactive t-cells
US20220193131A1 (en) 2018-12-19 2022-06-23 Iovance Biotherapeutics, Inc. Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
JP2022553389A (en) 2019-10-25 2022-12-22 アイオバンス バイオセラピューティクス，インコーポレイテッド Gene editing of tumor-infiltrating lymphocytes and its use in immunotherapy
JP2023506734A (en) 2019-12-11 2023-02-20 アイオバンス バイオセラピューティクス，インコーポレイテッド Process for the production of tumor-infiltrating lymphocytes (TIL) and methods of using same
JP2023507432A (en) 2019-12-20 2023-02-22 インスティル バイオ （ユーケイ） リミテッド Devices and methods for isolating tumor-infiltrating lymphocytes and uses thereof
BR112022021020A2 (en) 2020-04-22 2023-02-14 Iovance Biotherapeutics Inc METHOD OF MANUFACTURING A CELL THERAPY PRODUCT, METHODS OF TREATMENT OF THE PATIENT WITH THE EXPANSION AND MANUFACTURED CELL THERAPY PRODUCT, AND, METHOD OF MANUFACTURING A CELL THERAPY PRODUCT
WO2021226085A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
JP2023523855A (en) 2020-05-04 2023-06-07 アイオバンス バイオセラピューティクス，インコーポレイテッド Method for producing tumor-infiltrating lymphocytes and their use in immunotherapy
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CA3195019A1 (en) 2020-10-06 2022-04-14 Maria Fardis Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2022078431A (en) * 2020-11-13 2022-05-25 東洋製罐グループホールディングス株式会社 Cell culture system and method of detecting proliferative properties of cells
WO2022125941A1 (en) 2020-12-11 2022-06-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022133149A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
US20240207318A1 (en) 2021-04-19 2024-06-27 Yongliang Zhang Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4377446A1 (en) 2021-07-28 2024-06-05 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
US20230187042A1 (en) 2021-10-27 2023-06-15 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
WO2023086803A1 (en) 2021-11-10 2023-05-19 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201845A (en) * 1976-04-12 1980-05-06 Monsanto Company Cell culture reactor
US4649118A (en) * 1984-04-05 1987-03-10 The Virtis Company, Inc. Cell culturing apparatus with improved stirring and filter means
US5248769A (en) * 1985-06-26 1993-09-28 Cetus Oncology Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4789601A (en) 1987-05-04 1988-12-06 Banes Albert J Biocompatible polyorganosiloxane composition for cell culture apparatus
US4839292B1 (en) * 1987-09-11 1994-09-13 Joseph G Cremonese Cell culture flask utilizing membrane barrier
US5707869A (en) * 1994-06-28 1998-01-13 Wolf; Martin L. Compartmentalized multiple well tissue culture plate
US5693537A (en) * 1994-06-28 1997-12-02 Wilson; John R. Compartmentalized tissue culture flask
JP3608664B2 (en) 1994-06-28 2005-01-12 ウィルソン・ウルフ・マニュファクチャリング・コーポレイション Compartmented tissue culture flask
US6228635B1 (en) * 1995-06-07 2001-05-08 Aastrom Bioscience, Inc. Portable cell growth cassette for use in maintaining and growing biological cells
US5728581A (en) * 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
US5585266A (en) * 1995-10-05 1996-12-17 Plitt; Cheryl A. Immobilized cell bioreactor
IL119310A (en) 1996-09-26 1999-07-14 Metabogal Ltd Cell/tissue culturing device and method
JPH10174581A (en) * 1996-12-16 1998-06-30 Kikkoman Corp Culture vessel
DE19935643A1 (en) * 1999-07-29 2001-02-01 Augustinus Bader Device for growing and / or treating cells
KR20060036908A (en) * 2003-05-22 2006-05-02 폴 코포레이션 Cell culturing device and system
CN103173354B (en) 2003-10-08 2017-07-14 威尔森沃尔夫制造公司 The method and device of cell culture is carried out using poromeric material
US8507266B2 (en) * 2003-11-04 2013-08-13 Case Western Reserve University Apparatus and method for tissue engineering
FR2866655B1 (en) 2004-02-20 2007-05-11 Cesco Bioengineering Co Ltd APPARATUS AND METHOD FOR THE PREPARATION AND CULTIVATION OF CELLS
JP4241525B2 (en) 2004-06-25 2009-03-18 三洋電機株式会社 Culture container, automatic subculture apparatus and subculture method
JP2006141328A (en) 2004-11-22 2006-06-08 Hitachi Medical Corp Culturing container and culturing device
AU2006252503A1 (en) * 2005-06-01 2006-12-07 Irm Llc Cell culture flasks, systems, and methods for automated processing
JP2007110996A (en) 2005-10-21 2007-05-10 Hitachi Medical Corp Cell culture container and cell culture device
CN101300340A (en) * 2005-11-01 2008-11-05 迈世耐特股份公司 Cell culture apparatus, cell culture method, cell culture program and cell culture system
US20100317102A1 (en) * 2006-01-17 2010-12-16 Tsutomu Suzuki Cell Culture Method and Automatic Culture System Using the Method
US7682822B2 (en) 2006-03-31 2010-03-23 Aastrom Biosciences, Inc. Ex vivo generated tissue system
WO2008073313A2 (en) 2006-12-07 2008-06-19 Wilson Wolf Manufacturing Corporation Highly efficient gas permeable devices and methods for culturing cells
US9410113B2 (en) * 2007-10-26 2016-08-09 St3 Development Corporation Bioreactor system for three-dimensional tissue stimulator

Also Published As

Publication number Publication date
JP2015516175A (en) 2015-06-11
WO2013173835A1 (en) 2013-11-21
JP7346526B2 (en) 2023-09-19
SG10201509930RA (en) 2016-01-28
AU2018201826B2 (en) 2019-10-03
IL307674A (en) 2023-12-01
IL271005A (en) 2020-01-30
AU2020200037B2 (en) 2022-03-31
JP2023159460A (en) 2023-10-31
CN104379727A (en) 2015-02-25
AU2020200037A1 (en) 2020-02-06
JP6986591B2 (en) 2021-12-22
SG10202111564SA (en) 2021-12-30
CA2872504A1 (en) 2013-11-21
JP2022020851A (en) 2022-02-01
CN112574949A (en) 2021-03-30
JP2018183187A (en) 2018-11-22
IL235443B (en) 2019-12-31
AU2022204865A1 (en) 2022-07-21
JP2020124198A (en) 2020-08-20
EP3800242A1 (en) 2021-04-07
AU2018201826C1 (en) 2020-02-20
JP6691584B2 (en) 2020-04-28
AU2013262485A1 (en) 2014-12-04
IL235443A0 (en) 2014-12-31
AU2018201826A1 (en) 2018-04-12
EP2850175A4 (en) 2015-12-16
EP2850175B1 (en) 2020-12-16
EP2850175A1 (en) 2015-03-25
JP6386447B2 (en) 2018-09-05
AU2013262485B2 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
SG11201407226WA (en) Improved methods of cell culture for adoptive cell therapy
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201806988UA (en) Improved differentiation method
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201903480TA (en) Cell culture device system and methods of use thereof
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201810286WA (en) Variable diameter bioreactors
SG11201807487WA (en) Generation of midbrain-specific organoids from human pluripotent stem cells
SG11201909931PA (en) Oligomeric particle reagents and methods of use thereof
SG11201408561YA (en) Tunable materials
SG11201805451TA (en) Immune effector cell therapies with enhanced efficacy
SG11201909331UA (en) Antigen-specific immune effector cells
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201808476SA (en) Recycling of polymer matrix composite
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201408303WA (en) Adhesive compositions of propylene-based and ethylene-based polymers
SG11201903032SA (en) Methods and compositions related to nk cell and anti-pdl1 cancer therapies
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201407710VA (en) Compositions comprising short-acting benzodiazepines
SG11201408536WA (en) METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF
SG11201407802WA (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
SG11201907285XA (en) Methods and kits for generating mimetic innate immune cells from pluripotent stem cells
SG11201408297XA (en) Porous graphene oxide materials
SG11201908075UA (en) A microneedle device